Literature DB >> 6673295

Sequential external counterpulsation (SECP) in China.

Z S Zheng, T M Li, H Kambic, G H Chen, L Q Yu, S R Cai, C Y Zhan, Y C Chen, S X Wo, G W Chen.   

Abstract

A new SECP was developed and is currently successfully used in more than 120 clinics in China. This sequenced counterpulsation device has the effect of milking more blood as pressure is applied on the extremities in succession (first distally then proximally) and in decreasing values (265 to 200 mm Hg). In comparison of the 4 types of counterpulsation, namely nonsequenced leg and 4 limb counterpulsation, and sequenced 4 limb and 4 limb with buttock balloons, the SECP with buttock balloons method raised the DA to appreciably higher levels with respect to DA amplitude and area. DA was raised 43.9% higher than that obtained with 4 limb SECP alone. From our experimental and clinical results, we conclude that SECP with buttock balloons is a far more effective method providing greater diastolic augmentation than previously reported in the literature. Two hundred angina and 52 AMI patients who had undergone the SECP treatment constitute the basis of this report. The present work represents an analysis of 6 yrs experience with studies on the design, development and clinical evaluation of the SECP method. Ninety-seven percent of the angina patients obtained long-term symptomatic relief. Relapse was minimal. In 95.7% of the AMI patients chest pain or shock symptoms were rapidly relieved. SECP with high DA appears to be very effective in improving myocardial blood supply and ventricular function. Moreover, the simplicity and advantages of this noninvasive sequenced counterpulsation method have been reported (1063 cases) from 31 clinics in China. This method is convenient, safe, and far more effective than conventional drug therapy for patients with acute and chronic ischemic myocardial disease.

Entities:  

Mesh:

Year:  1983        PMID: 6673295

Source DB:  PubMed          Journal:  Trans Am Soc Artif Intern Organs        ISSN: 0066-0078


  9 in total

1.  Cardiovascular responses to external counterpulsation: a computer simulation.

Authors:  J Bai; K Ying; D Jaron
Journal:  Med Biol Eng Comput       Date:  1992-05       Impact factor: 2.602

2.  The Effects of Enhanced External Counterpulsation on Cardiac Electrophysiologic Properties of Patients with Ischemic Heart Disease and Refractory Angina at Function Class II-III.

Authors:  Fariborz Akbarzadeh; Yaghoub Salekzamani; Amir Shahram Beigzdeh
Journal:  J Cardiovasc Thorac Res       Date:  2011-05-28

3.  What's in the works for refractory hypertension beyond drugs and diet?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-12-17       Impact factor: 3.738

4.  Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-03-01

5.  A historical perspective towards a non-invasive treatment for patients with atherosclerosis.

Authors:  W Slijkhuis; W Mali; Y Appelman
Journal:  Neth Heart J       Date:  2009-04       Impact factor: 2.380

6.  Predictors of good functional outcome in counterpulsation-treated recent ischaemic stroke patients.

Authors:  Wenhua Lin; Jinghao Han; Xiangyan Chen; Li Xiong; Ho Wan Leung; Thomas W Leung; Yannie Soo; Lawrence Ka Sing Wong
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

Review 7.  Enhanced external counterpulsation in rehabilitation of erectile dysfunction: a narrative literature review.

Authors:  Seyed Ahmad Raeissadat; Atefeh Javadi; Farzad Allameh
Journal:  Vasc Health Risk Manag       Date:  2018-12-03

8.  Aortic counterpulsation for myocardial support: Towards a new paradigm.

Authors:  Arindam Choudhury
Journal:  Ann Card Anaesth       Date:  2019 Jul-Sep

9.  Chinese consensus statement on the evaluation and intervention of collateral circulation for ischemic stroke.

Authors:  Li-Ping Liu; An-Ding Xu; Lawrence K S Wong; David Z Wang; Yong-Jun Wang
Journal:  CNS Neurosci Ther       Date:  2014-02-05       Impact factor: 5.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.